Trial Outcomes & Findings for Brain Metabolism in Polycystic Ovary Syndrome (NCT NCT02409914)

NCT ID: NCT02409914

Last Updated: 2019-05-02

Results Overview

Global brain glucose uptake was quantified using FDG with dynamic positron emission tomography.

Recruitment status

COMPLETED

Target enrollment

7 participants

Primary outcome timeframe

Single point in time (day 1)

Results posted on

2019-05-02

Participant Flow

Women with PCOS diagnosed during a clinical examination using the Rotterdam criteria were recruited.

Participant milestones

Participant milestones
Measure
POLYCYSTIC OVARY SYNDROME (PCOS)
Women with PCOS. FDG PET scan,T1-weight MRI and a blood sample for the evaluation of insulin resistance were obtained within an average time frame of 3 weeks.
Overall Study
STARTED
7
Overall Study
COMPLETED
7
Overall Study
NOT COMPLETED
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Brain Metabolism in Polycystic Ovary Syndrome

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
POLYCYSTIC OVARY SYNDROME (PCOS)
n=7 Participants
Women with PCOS diagnosed during a clinical examination using the Rotterdam criteria. PET and MRI exams: FDG PET scan and T1-weight MRI were obtained within an average time frame of 3 weeks.
Age, Continuous
25 years
STANDARD_DEVIATION 6 • n=5 Participants
Sex: Female, Male
Female
7 Participants
n=5 Participants
Sex: Female, Male
Male
0 Participants
n=5 Participants

PRIMARY outcome

Timeframe: Single point in time (day 1)

Global brain glucose uptake was quantified using FDG with dynamic positron emission tomography.

Outcome measures

Outcome measures
Measure
Polycystic Ovary Syndrome (PCOS)
n=7 Participants
Women with PCOS.
Global Brain Glucose PET Uptake
34.9 umol/100 g/min
Standard Deviation 3.0

PRIMARY outcome

Timeframe: Single point in time (day 2)

T1-weighted brain MR images were obtained on a 1.5 Tesla scanner. Regional volumes were determined using FreeSurfer Suite 5.0 software.

Outcome measures

Outcome measures
Measure
Polycystic Ovary Syndrome (PCOS)
n=7 Participants
Women with PCOS.
Brain MR Volumes
Superior frontal cortex
22.6 ml
Standard Deviation 2.0
Brain MR Volumes
Supramarginal cortex
10.3 ml
Standard Deviation 1.4

PRIMARY outcome

Timeframe: Single point in time (day 1 during the FDG PET)

The homeostasis model assessment computational method was used to estimate insulin resistance (HOMA2-IR) from fasting plasma glucose and insulin. The HOMA2-IR is the reciprocal of insulin sensitivity (%S), as a percentage of a normal reference population (normal young adult). A higher score indicates a lower insulin sensitivity.

Outcome measures

Outcome measures
Measure
Polycystic Ovary Syndrome (PCOS)
n=7 Participants
Women with PCOS.
Insulin Resistance (HOMA2-IR)
0.7 HOMA2-IR score
Standard Deviation 0.3

Adverse Events

POLYCYSTIC OVARY SYNDROME (PCOS)

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Stephen Cunnane

USherbrooke

Phone: 1-819-780-2220

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place